The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: A mini review

Current Vascular Pharmacology

Volumn 7, Issue 4, 2009, Pages 557-569

  Guazzi, Marco ^a   Areria, Ross ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerobic capacity; Pharmacologic; Ventilatory efficiency; Ventilatory expired gas

Indexed keywords

ALACEPRIL; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; METOPROLOL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SPIRONOLACTONE;

ACCURACY; AEROBIC CAPACITY; BETA ADRENERGIC RECEPTOR BLOCKING; CARBON DIOXIDE TENSION; CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG RESPONSE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LUNG MINUTE VOLUME; MONOTHERAPY; OPTIMAL DRUG DOSE; OXYGEN CONSUMPTION; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY FUNCTION; REVIEW; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART FAILURE; HEMODYNAMICS; HUMANS; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PULMONARY VENTILATION;

EID: 70349659625     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109789043955     Document Type: Review

References (102)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
2. Bonow RO, Bennett S, Casey DEJ, Ganiats TG, Hlatky MA, Konstam MA, et al. ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): Endorsed by the Heart Failure Society of America. Circulation 2005; 112: 1853-87.
3. Patel MD, Katz SD. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. Am J Cardiol 2005; 96: 47-51.
4. Meyer K, Westbrook S, Schwaibold M, Hajric R, Peters K, Roskamm H. Short-term reproducibility of cardiopulmonary measurements during exercise testing in patients with severe chronic heart failure. Am Heart J 1997; 134: 20-6.
5. Gibbons RJ, Balady GJ, Timothy BJ, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40: 1531-40.
6. Arena R, Myers J, Guazzi M. The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review. Heart Fail Rev 2007; 13: 245-69.
7. Arena R, Humphrey R, Peberdy MA, Madigan M. Predicting peak oxygen consumption during a conservative ramping protocol: implications for the heart failure population. J Cardiopulm Rehabil 2003; 23: 183-9.
8. Agostoni P, Bianchi M, Moraschi A, Palermo P, Cattadori G, La Gioia R, et al. Work-rate affects cardiopulmonary exercise test results in heart failure. Eur J Heart Fail 2005; 7: 498-504.
9. Arena R, Myers J, Williams MA, Gulati M, Kligfield P, Balady GJ, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation 2007; 116: 329-43.
10. Piepoli MF, Corra U, Agostoni PG, Belardinelli R, Cohen-Solal A, Hambrecht R, et al. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation Part II: How to perform cardiopulmonary exercise testing in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2006; 13: 300-11.
11. Piepoli MF, Corra U, Agostoni PG, Belardinelli R, Cohen-Solal A, Hambrecht R, et al. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation. Part I: definition of cardiopulmonary exercise testing parameters for appropriate use in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2006; 13: 150-64.
12. Piepoli MF, Corra U, Agostoni PG, et al. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation Part III: Interpretation of cardiopulmonary exercise testing in chronic heart failure and future applications. Eur J Cardiovasc Prev Rehabil 2006; 13: 485-94.
13. Guazzi M, Pontone G, Brambilla R, Agostoni P, Reina G. Alveolar-capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J 2002; 23: 467-76.
14. Ponikowski P, Chua TP, Piepoli M, Banasiak W, Anker SD, Szelemej R, et al. Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. Am J Cardiol 1998; 82: 338-44.
15. Reindl I, Wernecke KD, Opitz C, Wensel R, König D, Dengler T, et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J 1998; 136: 778-85.
16. Myers J, Dziekan G, Goebbels U, Dubach P. Influence of high-intensity exercise training on the ventilatory response to exercise in patients with reduced ventricular function. Med Sci Sports Exerc 1999; 31: 929-37.
17. Kruger S, Graf JU, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40: 718-22.
18. Passino C, Poletti R, Bramanti F, Prontera C, Clerico A, Emdin M. Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. Eur J Heart Fail 2006; 8: 46-53.
19. Scardovi AB, De Maria R, Coletta C, Aspromonte N, Perna S, Infusino T, et al. Brain natriuretic peptide is a reliable indicator of ventilatory abnormalities during cardiopulmonary exercise test in heart failure patients. Med Sci Monit 2006; 12: CR191-CR5.
20. Tanabe Y, Nakagawa I, Ito E, Suzuki K. Hemodynamic basis of the reduced oxygen uptake relative to work rate during incremental exercise in patients with chronic heart failure. Int J Cardiol 2002; 83: 57-62.
21. Matsumoto A, Itoh H, Eto Y, Kobayashi T, Kato M, Omata M, et al. End-tidal CO2 pressure decreases during exercise in cardiac patients: association with severity of heart failure and cardiac output reserve. J Am Coll Cardiol 2000; 36: 242-9.
22. Metra M, Faggiano P, D'Aloia A, Nodari S, Gualeni A, Raccagni D, et al. Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. J Am Coll Cardiol 1999; 33: 943-50.
23. Myers J, Gujja P, Neelagaru S, Burkhoff D. Cardiac output and cardiopulmonary responses to exercise in heart failure: application of a new bio-reactance device. J Cardiac Fail 2007; 13: 629-36.
24. Myers J. Principles of exercise prescription for patients with chronic heart failure. Heart Fail Rev 2008; 13: 61-8.
25. Weber KT, Janicki JS, McElroy PA. Determination of aerobic capacity and the severity of chronic cardiac and circulatory failure. Circulation 1987; 76: VI40-V5.
26. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-86.
27. Myers J, Gullestad L, Vagelos R, et al. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. Am Heart J 2000; 139: 78-84.
28. Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO2 and VE/ VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J 2004; 147: 354-60.
29. Mezzani A, Corra U, Bosimini E, Giordano A, Giannuzzi P. Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity. Am Heart J 2003; 145: 1102-7.
30. Arena R, Myers J, Aslam S, Varughese EB, Peberdy MA. Technical considerations related to the minute ventialtion/carbon dioxide output slope in patients with heart failure. Chest 2003; 124: 720-7.
31. Bard RL, Gillespie BW, Clarke NS, Egan TG, Nicklas JM. Determining the best ventilatory efficiency measure to predict mortality in patients with heart failure. J Heart Lung Transplant 2006; 25: 589-95.
32. Tabet JY, Beauvais F, Thabut G, Tartiere JM, Logeart D, Cohen-Solal A. A critical appraisal of the prognostic value of the VE/VCO2 slope in chronic heart failure. J Cardiovasc Risk 2003; 10: 267-72.
33. Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. Circulation 1988; 77: 552-9.
34. Guazzi M, Reina G, Tumminello G, Guazzi MD. Alveolar-capillary membrane conductance is the best pulmonary function correlate of exercise ventilation efficiency in heart failure patients. Eur J Heart Fail 2005; 7: 1017-22.
35. Wada O, Asanoi H, Miyagi K, Ishizaka S, Kameyama T, Seto H, et al. Importance of abnormal lung perfusion in excessive exercise ventilation in chronic heart failure. Am Heart J 1993; 125: 790-8.
36. Ponikowski P, Francis DP, Piepoli MF, Davies LC, Chua TP, Davos CH, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001; 103: 967-72.
37. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007; 115: 2410-7.
38. Francis DP, Shamim W, Davies LC, Piepoli MF, Ponikowski P, Anker SD. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J 2000; 21: 154-61.
39. Pierpont GL, Voth EJ. Assessing autonomic function by analysis of heart rate recovery from exercise in healthy subjects. Am J Cardiol 2004; 94: 64-8.
40. Imai K, Sato H, Hori M, Ozaki H, Yokoyama H, Takeda H, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24: 1529-35.
41. Fei DY, Arena R, Arrowood JA, Kraft KA. Relationship between arterial stiffness and heart rate recovery in apparently healthy adults. Vasc Health Risk Manage 2005; 1: 85-9.
42. Gibbons RJ. Abnormal heart-rate recovery after exercise. Lancet 2002; 359: 1536-7.
43. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999; 341: 1351-7.
44. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001; 37: 1558-64.
45. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000; 284: 1392-8.
46. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is apredictor of mortality, independent of the angiographic severity of coronary disease*1. J Am Coll Cardiol 2003; 42: 831-8.
47. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation 2001; 104: 1911-6.
48. Messinger-Rapport B, Pothier Snader CE, Blackstone EH, Yu D, Lauer MS. Value of exercise capacity and heart rate recovery in older people. J Am Geriatr Soc 2003; 51: 63-8.
49. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA 2006; 295: 784-92.
50. Arena R, Guazzi M, Myers J, Peberdy MA. Prognostic value of heart rate recovery in patients with heart failure. Am Heart J 2006; 151: 851.e7-13.
51. Bilsel T, Terzi S, Akbulut T, Sayar N, Hobikoglu G, Yesilcimen K. Abnormal heart rate recovery immediately after cardiopulmonary exercise testing in heart failure patients. Int Heart J 2006; 47: 431-40.
52. Lipinski MJ, Vetrovec GW, Gorelik D, Froelicher VF. The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction. J Card Fail 2005; 11: 624-30.
53. Corra U, Giordano A, Bosimini E, Mezzani A, Piepoli M, Coats AJ, et al. Oscillatory ventilation during exercise in patients with chronic heart failure: clinical correlates and prognostic implications. Chest 2002; 121: 1572-80.
54. Guazzi M, Arena R, Ascione A, Piepoli M, Guazzi MD. Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: an unfavorable combination with high prognostic value. Am Heart J 2007; 153: 859-67.
55. Arena R, Peberdy MA, Myers J, Guazzi M, Tevald M. Prognostic value of resting end-tidal carbon dioxide in patients with heart failure. Int J Cardiol 2006; 109: 351-8.
56. Arena R, Guazzi M, Myers J. Prognostic value of end-tidal carbon dioxide during exercise testing in heart failure. Int J Cardiol 2007; 117: 103-8.
57. Koike A, Koyama Y, Itoh H, Adachi H, Marumo F, Hiroe M. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild to moderate heart failure. Jpn Circ J 2000; 64: 915-20.
58. Davies LC, Wensel R, Georgiadou P, Cicoira M, Coats AJ, Piepoli MF. Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. Eur Heart J 2006; 27: 684-90.
59. Arena R, Myers J, Hsu L, Peberdy MA, Pinkstaff S, Bensimhon D, et al. The minute ventilation/carbon dioxide production slope is prognostically superior to the oxygen uptake efficiency slope. J Card Fail 2007; 13: 462-9.
60. Kataoka M, Satoh T, Yoshikawa T, Nakamura I, Kohno T, Yoshizawa A, et al. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. Circ J 2008; 72: 358-63.
61. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: Is [beta] selectivity relevant? Eur J Heart Fail 2007; 9: 827-33.
62. Witte KK, Thackray S, Nikitin NP, Cleland JG, Clark AL. The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure. Eur J Heart Fail 2005; 7: 612-7.
63. Castro P, Vukasovic JL, Chiong M, Díaz-Araya G, Alcaino H, Copaja M, et al. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 1033-9.
64. Wolk R, Johnson BD, Somers VK, Allison TG, Squires RW, Gau GT, et al. Effects of [beta]-blocker therapy on ventilatory responses to exercise in patients with heart failure. J Card Fail 2005; 11: 333-9.
65. Taniguchi Y, Ueshima K, Chiba I, Segawa I, Kobayashi N, Saito M, et al. A New method using pulmonary gas-exchange kinetics to evaluate efficacy of {beta}-blocking agents in patients with dilated cardiomyopathy. Chest 2003; 124: 954-61.
66. Agostoni P, Guazzi M, Bussotti M, De Vita S, Palermo P. Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. Chest 2002; 122: 2062-7.
67. Dubach P, Myers J, Bonetti P, Schertler T, Froelicher V, Wagner D, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 2002; 143: 676-83.
68. Gullestad L, Manhenke C, Aarsland T, Skårdal R, Fagertun H, Wikstrand J, et al. Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. Eur J Heart Fail 2001; 3: 463-8.
69. Guazzi M, Agostoni P, Matturri M, Pontone G, Guazzi MD. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999; 138: 460-7.
70. Racine N, Blanchet M, Ducharme A, Marquis J, Boucher JM, Juneau M, et al. Decreased heart rate recovery after exercise in patients with congestive heart failure: Effect of [beta]-blocker therapy. J Card Fail 2003; 9: 296-302.
71. Agostoni P, Contini M, Magini A, Apostolo A, Cattadori G, Bussotti M, et al. Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. Eur J Heart Fail 2006; 8: 729-35.
72. Bouzamondo A, Hulot JS, Sanchez P, Cucherat M, Lechat P. Beta-blocker treatment in heart failure. Fundam Clin Pharmacol 2001; 15: 95-109.
73. Vonder Muhll I, Liu, P Webb G. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease. Int J Cardiol 2004; 97: 25-33.
74. Waagstein F, Stromblad O, Andersson B, Böhm M, Darius M, Delius W, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail 2003; 5: 679-91.
75. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei CL. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol vs carvedilol. Circulation 2000; 102: 546-51.
76. Tanabe Y, Hosaka Y, Ito M, Ito E, Suzuki K. Significance of end-tidal P(CO(2)) response to exercise and its relation to functional capacity in patients with chronic heart failure. Chest 2001; 119: 811-7.
77. Koike A, Hiroe M, Adachi H, Yajima T, Yamauchi Y, Nogami A, et al. Oxygen uptake kinetics are determined by cardiac function at onset of exercise rather than peak exercise in patients with prior myocardial infarction. Circulation 1994; 90: 2324-32.
78. Kinugawa T, Osaki S, Kato M, Ogino K, Shimoyama M, Tomikura Y, et al. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. Clin Exp Pharmacol Physiol 2002; 29: 1060-5.
79. Guazzi M, Melzi G, Marenzi GC, Agostoni P. Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. Clin Pharmacol Ther 1999; 65: 319-327.
80. McConnell TR, Menapace FJ Jr, Hartley LH, Pfeffer MA. Captopril reduces the VE/VCO2 ratio in myocardial infarction patients with low ejection fraction. Chest 1998; 114: 1289-94.
81. Akbulut T, Akgoz H, Dayi SU, Celik SE, Gurkan U, Tayyareci G. Evaluation of enalapril+losartan treatment with cardiopulmonary exercise test in patients with left ventricular dysfunction. Angiology 2006; 57: 181-6.
82. Dayi SU, Akbulut T, Akgoz H, Terzi S, Sayar N, Aydin A, et al. Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction. Acta Cardiol 2005; 60: 373-7.
83. Kinugawa T, Kato M, Ogino K, Osaki S, Igawa O, Hisatome I, et al. Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. Jpn J Physiol 2004; 54: 15-21.
84. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2.
85. Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol 1999; 84: 1038-43.
86. Agostoni P, Magini A, Andreini D, et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J 2005; 26: 159-64.
87. Kinugawa T, Ogino K, Kato M, Furuse Y, Shimoyama M, Mori M, et al. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. Gen Pharmacol 1998; 31: 93-9.
88. Bhatia V, Bhatia R, Mathew B. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies. Cardiol Rev 2005; 13: 297-303.
89. Abraham MR, Olson LJ, Joyner MJ, Turner ST, Beck KC, Johnson BD. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation 2002; 106: 1794-9.
90. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14: 189-97.
91. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59-66.
92. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-62.
93. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-44.
94. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44: 2339-48.
95. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097-103.
96. Guazzi M, Arena R, Pinkstaff S, Guazzi MD. Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol 2009, In Press. doi:10.1016/j.ijcard.2008.04.061
97. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005; 127: 1647-53.
98. O'Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving {beta}-blockers. Circulation 2005; 111: 2313-8.
99. Sola S, Mir MQS, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332-7.
100. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Exp Opin Pharmacother 2007; 8: 3061-8.
101. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant 2008; 27: 435-41.
102. Guazzi M, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol 2005; 46: 1883-90.